

S11 Table. Comparison of median overall survival and progression-free survival between ICT+CCRT vs. CT

Treatment	Median survival (Range) (n)	No.	Progression-free survival (Range) (n)	No.
All	13.32 (7.8-26.6)	49	8.27 (4.2-17.8)	38
CT	13.07 (7.8-26.6)	24	7.39 (4.2-17.8)	15
ICT+CCRT	13.57 (8-19.2)	25	8.97 (5.1-12.5)	23
Randomization				
No				
CT	15.74 (13.5-26.6)	7	8.14 (6-17.8)	5
ICT+CCRT	13.27 (8-19.2)	21	8.71 (5.1-12.5)	19
Yes				
CT	12.18 (7.8-23.9)	16	6.9 (4.2-12.6)	9
ICT+CCRT	14.75 (13.4-15.2)	4	10.01 (6.5-12)	4
Resectability status				
Unresectable only				
CT	12.58 (7.8-23.9)	20	6.91 (4.2-12.6)	12
ICT+CCRT	13.24 (8.0-16.8)	20	8.77 (5.1-12.0)	18
Borderline and unresectable				
CT	17.21 (13.5-26.6)	4	11.45 (10.0-17.8)	3
ICT+CCRT	15.31 (11.8-19.2)	5	9.94 (6.5-12.5)	5
No. of chemotherapy agents				
One				
CT	12.25 (8.2-16.5)	12	6.86 (4.2-8.4)	9
ICT+CCRT	13.92 (8-19.2)	6	9.2 (7.1-12.5)	5
Two or more				
CT	14.63 (7.8-26.6)	12	10.95 (7.3-17.8)	6
ICT+CCRT	13.35 (8.8-16.8)	19	8.97 (5.1-12)	18
ICT duration				
ICT+CCRT with ICT < 3 mo	13.14 (8-19)	18	8.53 (5.1-12)	16
ICT+CCRT with ICT ≥ 3 mo	14.59 (13.4-15)	7	10.02 (8.1-12)	7
Maintenance CT				
ICT+CCRT without Maintenance CT	12.96 (8.8-17)	10	9.05 (5.1-12)	9
ICT+CCRT with Maintenance CT	13.94 (8-19)	15	8.92 (6-12)	14
RT dosage				
ICT+CCRT with RT dosage < 50 Gy	12.85 (10.8-14)	5	8.95 (7.8-11)	5
ICT+CCRT with RT dosage ≥ 50 Gy	13.72 (8-19)	20	8.97 (5.1-12)	18
Radio-sensitizer				

ICT+CCRT with gemcitabine	12.51 (8-17)	8	8.35 (5.1-10)	7
ICT+CCRT with fluorouracil	14.84 (11.7-19)	12	9.75 (6.5-12)	11
ICT+CCRT with other	12.51 (10.8-14)	3	8.86 (7.8-11)	3

ICT, induction chemotherapy; CCRT, chemoradiation; CT, chemotherapy.